Good morning, everyone, and welcome to another working week. We hope the weekend respite was somehow relaxing and invigorating, because that oh-so predictable routine of Zoom meetings, Skype calls, and deadlines has returned. After all, the world keeps spinning. So why not give it a little push with a cup of stimulation in hand? Our choice today is vanilla caramel cream. Feel free to join us. Meanwhile, here are a few items of interest to help you on your own journey. We hope all goes well today and, of course, do stay in touch. …

GlaxoSmithKline (GSK) and Sanofi (SNY) have started a new clinical trial of their protein-based Covid-19 vaccine candidate, reviving their efforts against the pandemic after a setback in December delayed the shot’s launch, Reuters writes. The drug makers aim to reach final testing in the second quarter, and if results are conclusive, hope to win approval by the fourth quarter after having initially targeted the first half of this year. In December 2020, the companies disclosed clinical trials showed an insufficient immune response in older people.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What’s included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Source: STATNEWS.COM

Leave a Reply

ArabicChinese (Simplified)EnglishFrenchGermanItalianJapanesePortugueseRussianSpanish

[mc4wp_form id="449"]